Cell
Hillstar Bio Launches with $67M to Develop Precision Immunotherapies for Autoimmune Diseases
Precision immunology, autoimmune diseases, TRBV9+ T cells, axial spondyloarthritis, Series A funding
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New
Lonza’s Vision for the Future: A Fireside Chat with New CEO Wolfgang Wienand
Lonza, Wolfgang Wienand, CDMO, Pharmaceutical manufacturing, Biologics, Cell and gene therapy, Small molecules, Leadership transition, Industry outlook
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
Daiichi turns to Nosis for AI-designed RNA delivery tech
Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease
BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal
Burning Mouth Syndrome, Abecma, BMS, Abecma
Cabaletta’s CABA-201 CAR-T Therapy Shows Promising Results in Lupus and Other Autoimmune Diseases
CABA-201, CAR-T therapy, lupus, autoimmune diseases, clinical trials, remission, B cell depletion
AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies
AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development
AbbVie and Xilio Therapeutics Collaborate on $2.1B Deal for Novel Tumor-Activated Immunotherapies
AbbVie, Xilio Therapeutics, T-cell engagers, tumor-activated immunotherapies, oncology, collaboration, biobucks deal
Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints
Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges